KRAS and colorectal carcinoma: Although KRAS G12C inhibitors suppress the mutant KRAS protein, the receptor tyrosine kinase (RTK, primarily EGFR in CRC)-mediated upstream feedback reactivation of the RAS-MAPK-signaling pathway may occur in a KRAS-G12C-independent manner, resulting in treatment resistance [69,70].